CommuniTreat

Company Overview

Snapshot

Founded in April 2021 by Nimrod Dahan, Itay Ben Mordechai, Dr. Tami Ehrmann Barr, and Dr. Hilik Marom, CommuniTreat operates with 1–10 employees. The company has secured funding across two rounds from Menmon, and has also received one grant. Its product, FRT, is currently in the Alpha stage.

Business overview

CommuniTreat develops an IP-backed bio-formula solution to manage overpopulated feral and invasive species. The company's core technology focuses on fertility control through a food-based contraceptive application, aiming to reduce reproductive rates and mitigate ecological and public health risks. CommuniTreat serves markets globally, including the United States and Europe, operating within the Agriculture & Food Technologies sector, specifically in Ag Tech and Precision Ag, and also has relevance in Health Tech & Life Sciences.

Company Intelligence Q&A

What is CommuniTreat's primary focus?

CommuniTreat focuses on strategic control of feral and invasive species populations using an IP-backed bio-formula solution to safely and effectively limit overpopulation.

When was CommuniTreat founded and by whom?

CommuniTreat was founded in April 2021 by Nimrod Dahan, Itay Ben Mordechai, Dr. Tami Ehrmann Barr, and Dr. Hilik Marom.

What is CommuniTreat's core technology?

CommuniTreat's core technology involves a food-based contraceptive application designed to reduce the reproductive rate of feral and invasive species, positioning fertility control as a cornerstone of integrated pest management.

What is CommuniTreat's current product stage?

CommuniTreat's product, FRT, is currently in the Alpha stage, indicating it is in an early development phase with ongoing testing and refinement.

Which markets does CommuniTreat target?

CommuniTreat targets global markets, including the United States and Europe, addressing issues in agriculture, public health, infrastructure, and biodiversity.